News articles about Enanta Pharmaceuticals (NASDAQ:ENTA) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Enanta Pharmaceuticals earned a news sentiment score of 0.08 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.7567999372622 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

A number of research firms recently issued reports on ENTA. J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $38.00 price target (up previously from $32.00) on shares of Enanta Pharmaceuticals in a research note on Wednesday, August 9th. Royal Bank Of Canada began coverage on shares of Enanta Pharmaceuticals in a research note on Thursday, September 14th. They set an “outperform” rating on the stock. Zacks Investment Research raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 11th. JMP Securities raised shares of Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 price target on the stock in a research note on Tuesday, July 11th. Finally, Robert W. Baird upped their price target on shares of Enanta Pharmaceuticals from $27.00 to $36.00 and gave the company a “neutral” rating in a research note on Tuesday, August 8th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $36.00.

Shares of Enanta Pharmaceuticals (ENTA) opened at 42.71 on Friday. The stock’s market cap is $815.33 million. Enanta Pharmaceuticals has a 1-year low of $22.17 and a 1-year high of $45.74. The company’s 50-day moving average is $41.09 and its 200-day moving average is $34.67.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, August 7th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.05. Enanta Pharmaceuticals had a negative net margin of 51.85% and a negative return on equity of 7.74%. The company had revenue of $7.51 million for the quarter, compared to analysts’ expectations of $8.08 million. During the same quarter in the previous year, the company posted ($0.06) EPS. The firm’s quarterly revenue was down 46.3% on a year-over-year basis. Equities analysts expect that Enanta Pharmaceuticals will post $1.14 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.dailypolitical.com/2017/09/24/enanta-pharmaceuticals-enta-given-media-sentiment-rating-of-0-08.html.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Insider Buying and Selling by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.